Jun 2026 (Q2 FY26) — Aug 3, 2026
ClearPoint Neuro Q2 FY26 — Strategic Reprioritization Towards Commercial Readiness and CAL Expansion
Read the full callClearPoint Neuro (CLPT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ClearPoint Neuro earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 10.9 | +18.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -94.2 | −32.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -11.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$9.17 +1.10% · +$0.1
Performance −63.9% 1Y
1Y: $25.38 on 17 Oct 2025 → $9.17. High $27.32 (20 Oct 2025), low $8.66 (30 Mar 2026).
- Previous close
- $9.07
- 52-week range
- $8.66 – $27.32
- One year
- −66.43%
Overview
- Symbol
- CLPT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ClearPoint Neuro earnings calls (CLPT)
Financials
What the filings say
Net profit, year on year: −94% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 8 | 8 | 9 | 9 | 10 | 12 | 11 |
| Operating profit | -5 | -6 | -6 | -6 | -5 | -7 | -8 | -10 |
| Operating margin | −63.5% | −72.1% | −72.6% | −61.6% | −59.5% | −67.7% | −69.9% | −94.2% |
| Interest | — | — | 0 | 0 | — | — | 1 | 1 |
| Profit before tax | -5 | -5 | -6 | -6 | -6 | -8 | -10 | -11 |
| Tax rate | −0.3% | 0.6% | −0.3% | −0.4% | −0.1% | −0.1% | −0.1% | 0.3% |
| Net profit | -5 | -5 | -6 | -6 | -6 | -8 | -10 | -11 |
| EPS ($ per share) | -0.18 | — | -0.22 | -0.21 | -0.21 | — | -0.32 | -0.38 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -107 | -113 | -120 | -134 | -150 | -172 | -191 | -217 |
| Total liabilities | 6 | 7 | 27 | 17 | 19 | 21 | 14 | 70 |
| Fixed assets | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 3 |
| Investments | — | — | — | 0 | 10 | 0 | — | — |
| Total assets | 8 | 12 | 30 | 66 | 55 | 43 | 39 | 98 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5 | -3 | -8 | -13 | -16 | -14 | -9 | -24 |
| Cash from investing | -0 | -0 | -0 | -0 | -11 | 9 | -0 | 1 |
| Cash from financing | -1 | 6 | 23 | 47 | 0 | 0 | 6 | 50 |
| Net cash flow | — | 3 | 14 | 34 | -26 | -4 | -3 | 27 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -1 |
| Free cash flow | -5 | -3 | -8 | -13 | -16 | -14 | -9 | -24 |
Insider filings
69 filings between Nov 21, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.47M
9 sales by 4 insiders
78% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 28
- Option exercise — converted options into shares
- 15
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BURNETT JOSEPH | — | $2.16M | Jun 29, 2026 |
| Klein Matthew B. | — | $185.4K | May 21, 2026 |
| Richards Timothy T. | — | $65.9K | Jun 1, 2026 |
| FALLON LYNNETTE C | — | $56.7K | May 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Richards Timothy T. Director | Award | 319 | $3.9K |
| Oct 1, 2026 | FLETCHER R JOHN Director | Award | 993 | $12.1K |
| Sep 2, 2026 | BURNETT JOSEPH CEO and President | Option exercise | 12,517 | $43.4K |
| Jul 1, 2026 | Richards Timothy T. Director | Award | 222 | $4.0K |
| Jul 1, 2026 | FLETCHER R JOHN Director | Award | 662 | $11.8K |
| Jun 30, 2026 | BURNETT JOSEPH CEO and President | Award | 1,361 | $16.2K |
| Jun 30, 2026 | STIGALL L. JEREMY Chief Business Officer | Award | 1,781 | $21.2K |
| Jun 30, 2026 | D'Alessandro Danilo Chief Financial Officer | Award | 1,085 | $12.9K |
| Jun 29, 2026 | BURNETT JOSEPH CEO and President | Sale 10b5-1 plan | 20,000 | $387.6K |
| Jun 29, 2026 | BURNETT JOSEPH CEO and President | Option exercise 10b5-1 plan | 20,000 | $50.0K |
| Jun 17, 2026 | BURNETT JOSEPH CEO and President | Sale 10b5-1 plan | 1,843 | $33.1K |
| Jun 17, 2026 | BURNETT JOSEPH CEO and President | Sale 10b5-1 plan | 60,000 | $1.07M |
| Jun 17, 2026 | BURNETT JOSEPH CEO and President | Option exercise 10b5-1 plan | 60,000 | $150.0K |
| Jun 4, 2026 | Richards Timothy T. Director | Option exercise | 500 | $5.0K |
| Jun 4, 2026 | Richards Timothy T. Director | Tax withheld | 376 | $5.0K |
| Jun 1, 2026 | Richards Timothy T. Director | Sale | 5,415 | $65.9K |
| May 21, 2026 | Klein Matthew B. Director | Sale | 16,000 | $185.4K |
| May 20, 2026 | FALLON LYNNETTE C Director | Sale 10b5-1 plan | 5,091 | $56.7K |
| May 19, 2026 | FALLON LYNNETTE C Director | Option exercise 10b5-1 plan | 12,417 | — |
| May 19, 2026 | JOHNSON B KRISTINE Director | Option exercise | 12,417 | — |
| May 19, 2026 | FLETCHER R JOHN Director | Option exercise | 12,417 | — |
| May 19, 2026 | Klein Matthew B. Director | Option exercise | 12,417 | — |
| May 19, 2026 | Richards Timothy T. Director | Option exercise | 12,417 | — |
| May 19, 2026 | Girin Pascal E R Director | Option exercise | 12,417 | — |
| May 19, 2026 | LIAU LINDA M. Director | Option exercise | 12,417 | — |
| Apr 1, 2026 | FLETCHER R JOHN Director | Award | 1,270 | $11.6K |
| Apr 1, 2026 | Girin Pascal E R Director | Award | 755 | $6.9K |
| Apr 1, 2026 | Richards Timothy T. Director | Award | 442 | $4.0K |
| Mar 19, 2026 | BURNETT JOSEPH CEO and President | Option exercise | 20,942 | $67.9K |
| Mar 12, 2026 | BURNETT JOSEPH CEO and President | Option exercise | 84,829 | — |
| Mar 12, 2026 | STIGALL L. JEREMY Chief Business Officer | Tax withheld | 15,151 | $174.7K |
| Mar 12, 2026 | STIGALL L. JEREMY Chief Business Officer | Option exercise | 30,995 | — |
| Mar 12, 2026 | SABRA MAZIN Chief Operating Officer | Tax withheld | 13,281 | $153.1K |
| Mar 12, 2026 | SABRA MAZIN Chief Operating Officer | Option exercise | 26,101 | — |
| Mar 12, 2026 | BURNETT JOSEPH CEO and President | Tax withheld | 43,161 | $497.6K |
| Mar 12, 2026 | D'Alessandro Danilo Chief Financial Officer | Tax withheld | 16,601 | $191.4K |
| Mar 12, 2026 | D'Alessandro Danilo Chief Financial Officer | Option exercise | 32,627 | — |
| Mar 11, 2026 | STIGALL L. JEREMY Chief Business Officer | Option exercise | 8,291 | — |
| Mar 11, 2026 | D'Alessandro Danilo Chief Financial Officer | Tax withheld | 2,109 | $24.5K |
| Mar 11, 2026 | D'Alessandro Danilo Chief Financial Officer | Option exercise | 4,145 | — |
| Mar 11, 2026 | STIGALL L. JEREMY Chief Business Officer | Tax withheld | 3,224 | $37.5K |
| Mar 6, 2026 | STIGALL L. JEREMY Chief Business Officer | Tax withheld | 6,913 | $69.1K |
| Mar 6, 2026 | BURNETT JOSEPH CEO and President | Option exercise | 47,407 | — |
| Mar 6, 2026 | SABRA MAZIN Chief Operating Officer | Option exercise | 13,827 | — |
| Mar 6, 2026 | STIGALL L. JEREMY Chief Business Officer | Option exercise | 17,778 | — |
| Mar 6, 2026 | BURNETT JOSEPH CEO and President | Tax withheld | 22,709 | $227.1K |
| Mar 6, 2026 | SABRA MAZIN Chief Operating Officer | Tax withheld | 7,036 | $70.4K |
| Mar 6, 2026 | D'Alessandro Danilo Chief Financial Officer | Tax withheld | 9,548 | $95.5K |
| Mar 6, 2026 | D'Alessandro Danilo Chief Financial Officer | Option exercise | 18,765 | — |
| Mar 3, 2026 | STIGALL L. JEREMY Chief Business Officer | Tax withheld | 4,506 | $39.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ClearPoint Neuro, Inc.
Free account. Everything above stays public.
Write why you follow ClearPoint Neuro, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading